Regeneron Pharmaceuticals (REGN) Equity Average (2009 - 2026)

Regeneron Pharmaceuticals' Equity Average history runs 18 years deep, the most recent figure standing at $31.3 billion for Q1 2026.

• In Q1 2026, Equity Average rose 6.71% year-over-year to $31.3 billion; the TTM figure through Mar 2026 stood at $31.3 billion (up 6.71% YoY), while the FY2025 annual figure was $30.3 billion, up 9.55% from the prior year.
• Equity Average was $31.3 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $31.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $31.3 billion in Q1 2026 to a low of $19.3 billion in Q1 2022.
• Historically, Equity Average has averaged $26.1 billion across 5 years, with a median of $26.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 68.17% in 2022, then increased 5.85% in 2025.
• A 5-year view of Equity Average shows it stood at $22.1 billion in 2022, then increased by 15.36% to $25.4 billion in 2023, then increased by 15.33% to $29.3 billion in 2024, then grew by 6.02% to $31.1 billion in 2025, then gained by 0.75% to $31.3 billion in 2026.
• The last three Equity Average figures came in at $31.3 billion (Q1 2026), $31.1 billion (Q4 2025), and $30.4 billion (Q3 2025), per Business Quant data.